CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.
Related Articles
CHMP Recommends First-Line Pembrolizumab Plus Chemo for Unresectable Non-Epithelioid Malignant Pleural Mesothelioma
The CHMP has recommended the approval of pembrolizumab plus chemotherapy for first-line unresectable non-epithelioid malignant pleural mesothelioma.
Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma
The CHMP has recommended the EU approval of isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.
Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer – OncoDaily
Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer / Camille Baudelin, cancer, Christophe Hennequin, Derek
Symposium | First-line BTK inhibitors in clinical practice: Case study clinic
During the Lymphoma Hub virtual symposium, entitled Customizing first-line BTK inhibitors for CLL Francesc Bosch presented a clinical case study and clinical data on BTK…
Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization The Ohio State University James…
Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York City, NY, and Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, discuss the biology of…
Home Page: Annals of Oncology
Published online: September 14, 2024 Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides…
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML
Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.
Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive NMIBC With CIS
Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.